Biologics include some of the most innovative and expensive drugs today. They also raise some of the more complex intellectual property (IP) strategies. Patents provide exclusivity in national markets for the molecules, and trade secrecy shrouds the complex, secret manufacturing processes. Academics, policymakers and industry experts question whether the IP arrangements undermine innovation, efficiency, and competition.
The symposium will focus on important policy issues for pharmaceutical biologics and competitive biosimilars. In particular, it will examine new ideas for innovative partnerships, trade secret disclosure, and evaluation of similarity. We will also consider how the legal architecture both encouraged and impeded the development and manufacturing of COVID-19 vaccines.
The 2023 CeBIL Symposium is organised by the Cambridge Centre for Law, Medicine and Life Sciences (LML) in combination with the Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) at the University of Copenhagen. The Symposium is generously supported by the Novo Nordisk Foundation.
For more information and to register please refer to the LML website.
If you have any queries about the Symposium, please contact LML via email at lml@law.cam.ac.uk.
Facebook 
X/Twitter 
Instagram 
YouTube 
Flickr 
LinkedIn